Adrián Alonso

Science magazine has named lenacapavir as breakthrough of the year. Lenacapavir is an injectable drug that prevents HIV infection for six months with near 100% efficacy. The publication notes its potential to dramatically reduce infections in high-risk populations, but also reminds that global roll-out will depend on affordability, manufacturing agreements and a robust health infrastructure. Approval of the drug is expected by 2025. 

"Equity in the distribution of vaccines is not a matter of charity; it benefits all countries," said Tedros Adhanom, director of the WHO. However, his data speak of a very unequal distribution: more than 80 % of the vaccines have gone to G20 countries, while poor countries, mostly African, have received only 0.6 %. Three Spanish experts analyze what went wrong.